ERBB2 and breast carcinoma: Interestingly, in the set of 26 breast cancer cells, there were also HER2-amplified cases, such as HCC1569, which showed relatively low sensitivity to lapatinib (Figure 4c), indicating that HER2 positivity does not necessarily imply HER2 addiction.